ReviewRevista medica del Instituto Mexicano del Seguro Social2024
[The role of immunosenescence and inflammaging in aging-associated diseases].
Review in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sex differences in middle-aged and old Wistar rats in response to long-term sulforaphane treatment for prevention of neuroinflammation, cognitive decline and brain senescence.Biogerontology · 2025Article
- Eastern Equine Encephalitis Virus: The Importance of Metabolism and Aging.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increase in the number of people with advanced age (> 60 years) worldwide, it is necessary to understand the processes that lead to healthy aging. Cellular senescence, immunosenescence and inflammaging are part of the natural process of aging and are associated with age-related diseases. Cellular senescence is characterized by the arrest of the cell cycle in the G1 phase. Senescent cells can be identified by different markers (surface or intracellular), by changes in their functions, and by their gene expression profile. Immunosenescence causes dysregulation of the immune response, with persistent (chronic) increases in inflammatory mediators and decreases in the effectiveness of immune effector responses, which promotes the development and severity of chronic-degenerative diseases and fragility. When immunosenescence is related with advanced age, it is known as inflammaging. New strategies to revert immunosenescence are currently being investigated, with senotherapy with senolytic drugs that eliminate senescent cells, and with senomorphic drugs that inhibit the secretion of senescence-promoting mediators. Senolytic drugs may be useful during the aging process, to delay, prevent and/or improve age-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.